Organon Ownership
| OGN Stock | USD 14.89 0.16 1.09% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Organon |
Organon Stock Ownership Analysis
About 82.0% of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 5.05. Organon last dividend was issued on the 12th of November 2024. Organon Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Organon Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon CO operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 9300 people. To find out more about Organon Co contact Kevin Ali at 551 430 6900 or learn more at https://www.organon.com.Besides selling stocks to institutional investors, Organon also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Organon's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Organon's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Organon Quarterly Liabilities And Stockholders Equity |
|
Organon Insider Trades History
Less than 1% of Organon Co are currently held by insiders. Unlike Organon's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Organon's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Organon's insider trades
Organon Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Organon is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Organon Co backward and forwards among themselves. Organon's institutional investor refers to the entity that pools money to purchase Organon's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deprince Race & Zollo Inc | 2024-06-30 | 3.4 M | Charles Schwab Investment Management Inc | 2024-09-30 | 3.3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.7 M | Slate Path Capital Lp | 2024-09-30 | 2.5 M | Thompson, Siegel & Walmsley Llc | 2024-09-30 | 2.3 M | Amvescap Plc. | 2024-06-30 | 2.2 M | Acadian Asset Management Llc | 2024-06-30 | 2.2 M | Private Management Group Inc | 2024-09-30 | 1.9 M | Fmr Inc | 2024-09-30 | 1.8 M | Blackrock Inc | 2024-06-30 | 32.6 M | Vanguard Group Inc | 2024-09-30 | 30.2 M |
Organon Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Organon insiders, such as employees or executives, is commonly permitted as long as it does not rely on Organon's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Organon insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Organon's latest congressional trading
Congressional trading in companies like Organon, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Organon by those in governmental positions are based on the same information available to the general public.
| 2021-06-15 | Representative Scott Franklin | Acquired Under $15K | Verify |
Organon Outstanding Bonds
Organon issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Organon uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Organon bonds can be classified according to their maturity, which is the date when Organon Co has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View | |
| US68622TAB70 Corp BondUS68622TAB70 | View | |
| US68622TAA97 Corp BondUS68622TAA97 | View |
Organon Corporate Filings
F4 | 8th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 1st of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 17th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Pair Trading with Organon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organon will appreciate offsetting losses from the drop in the long position's value.Moving together with Organon Stock
Moving against Organon Stock
| 0.75 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.73 | VERA | Vera Therapeutics | PairCorr |
| 0.72 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.72 | VRDN | Viridian Therapeutics | PairCorr |
| 0.55 | DSGN | Design Therapeutics | PairCorr |
The ability to find closely correlated positions to Organon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organon Co to buy it.
The correlation of Organon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organon moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organon Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.081 | Dividend Share 1.12 | Earnings Share 5.05 | Revenue Per Share 24.984 | Quarterly Revenue Growth 0.041 |
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.